5-HT2B antagonism arrests non-canonical TGF-β1-induced valvular myofibroblast differentiation

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 5, 2012, Pages 707-714

  Hutcheson, Joshua D ^a   Ryzhova, Larisa M ^a   Setola, Vincent ^b   Merryman, W David ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Calcification; Heart valves; Serotonin receptors; TGF 1

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 METHYL 5 ISOTHIAZOLYL)UREA; 1 [3 FLUORO 5 (3 PYRIDYL)PHENYLCARBAMOYL] 5 METHOXY 6 TRIFLUOROMETHYLINDOLINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN TYROSINE KINASE; SEROTONIN 2B RECEPTOR; SEROTONIN ANTAGONIST; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; AORTA VALVE; AORTA VALVE DISEASE; AORTA VALVE INTERSTITIAL CELL; ARTICLE; CELL ACTIVATION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL ISOLATION; CELL TYPE; CELL VIABILITY; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART VALVE; IN VITRO STUDY; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SWINE;

ACTINS; ANIMALS; AORTIC DISEASES; AORTIC VALVE; CALCINOSIS; CELL DIFFERENTIATION; CELLS, CULTURED; GENE EXPRESSION; INDOLES; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MYOFIBROBLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; SRC-FAMILY KINASES; SUS SCROFA; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GROWTH FACTOR BETA1; UREA;

SUS;

EID: 84867398372     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.08.012     Document Type: Article

References (43)

1. Walker G.A., Masters K.S., Shah D.N., Anseth K.S., Leinwand L.A. Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 2004, 95:253-260.
2. Bertipaglia B., Ortolani F., Petrelli L., Gerosa G., Spina M., Pauletto P., et al. Cell characterization of porcine aortic valve and decellularized leaflets repopulated with aortic valve interstitial cells: the VESALIO Project (Vitalitate Exornatum Succedaneum Aorticum Labore Ingenioso Obtenibitur). Ann Thorac Surg 2003, 75:1274-1282.
3. Akat K., Borggrefe M., Kaden J.J. Aortic valve calcification: basic science to clinical practice. Heart 2009, 95:616-623.
4. Jian B., Narula N., Li Q.Y., Mohler E.R., Levy R.J. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 2003, 75:457-465. discussion 65-6.
5. Merryman W.D., Lukoff H.D., Long R.A., Engelmayr G.C., Hopkins R.A., Sacks M.S. Synergistic effects of cyclic tension and transforming growth factor-beta1 on the aortic valve myofibroblast. Cardiovasc Pathol 2007, 16:268-276.
6. Howe P.H. Transforming growth factor Beta. The Cytokine Handbook 2003, 1119-1141. Elsevier Science, London. 4th ed. A.W. Thomson, M.T. Lotze (Eds.).
7. Olieslagers S., Pardali E., Tchaikovski V., ten Dijke P., Waltenberger J. TGF-beta1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus. Cardiovasc Res 2011, 91:510-518.
8. You J., Reilly G.C., Zhen X., Yellowley C.E., Chen Q., Donahue H.J., et al. Osteopontin gene regulation by oscillatory fluid flow via intracellular calcium mobilization and activation of mitogen-activated protein kinase in MC3T3-E1 osteoblasts. J Biol Chem 2001, 276:13365-13371.
9. Compton L.A., Potash D.A., Mundell N.A., Barnett J.V. Transforming growth factor-beta induces loss of epithelial character and smooth muscle cell differentiation in epicardial cells. Dev Dyn 2006, 235:82-93.
10. Galliher A.J., Schiemann W.P. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 2007, 67:3752-3758.
11. Fitzgerald L.W., Burn T.C., Brown B.S., Patterson J.P., Corjay M.H., Valentine P.A., et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000, 57:75-81.
12. Rothman R.B., Baumann M.H., Savage J.E., Rauser L., McBride A., Hufeisen S.J., et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000, 102:2836-2841.
13. Levy R.J. Serotonin transporter mechanisms and cardiac disease. Circulation 2006, 113:2-4.
14. Jian B., Xu J., Connolly J., Savani R.C., Narula N., Liang B., et al. Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 2002, 161:2111-2121.
15. Fabre A., Marchal-Somme J., Marchand-Adam S., Quesnel C., Borie R., Dehoux M., et al. Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur Respir J 2008, 32:426-436.
16. Jaffre F., Bonnin P., Callebert J., Debbabi H., Setola V., Doly S., et al. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res 2009, 104:113-123.
17. Maish M.S., Hoffman-Kim D., Krueger P.M., Souza J.M., Harper J.J., Hopkins R.A. Tricuspid valve biopsy: a potential source of cardiac myofibroblast cells for tissue-engineered cardiac valves. J Heart Valve Dis 2003, 12:264-269.
18. Forbes I.T., Jones G.E., Murphy O.E., Holland V., Baxter G.S. N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: a novel, high-affinity 5-HT2B receptor antagonist. J Med Chem 1995, 38:855-857.
19. Bromidge S.M., Dabbs S., Davies D.T., Davies S., Duckworth D.M., Forbes I.T., et al. Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem 2000, 43:1123-1134.
20. Qiu P., Feng X.H., Li L. Interaction of Smad3 and SRF-associated complex mediates TGF-beta1 signals to regulate SM22 transcription during myofibroblast differentiation. J Mol Cell Cardiol 2003, 35:1407-1420.
21. Solway J., Seltzer J., Samaha F.F., Kim S., Alger L.E., Niu Q., et al. Structure and expression of a smooth muscle cell-specific gene, SM22 alpha. J Biol Chem 1995, 270:13460-13469.
22. Fisher C.I., Chen J., Merryman W.D. Calcific nodule morphogenesis by heart valve interstitial cells is strain dependent. Biomech Model Mechanobiol 2012.
23. Wrana J.L., Attisano L., Carcamo J., Zentella A., Doody J., Laiho M., et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992, 71:1003-1014.
24. Brabek J., Constancio S.S., Shin N.Y., Pozzi A., Weaver A.M., Hanks S.K. CAS promotes invasiveness of Src-transformed cells. Oncogene 2004, 23:7406-7415.
25. Mohler E.R., Gannon F., Reynolds C., Zimmerman R., Keane M.G., Kaplan F.S. Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522-1528.
26. Benton J.A., Kern H.B., Leinwand L.A., Mariner P.D., Anseth K.S. Statins block calcific nodule formation of valvular interstitial cells by inhibiting alpha-smooth muscle actin expression. Arterioscler Thromb Vasc Biol 2009, 29:1950-1957.
27. Balachandran K., Sucosky P., Jo H., Yoganathan A.P. Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic protein-dependent manner. Am J Pathol 2010, 177:49-57.
28. Wendt M.K., Schiemann W.P. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res 2009, 11:R68.
29. Yu L., Hebert M.C., Zhang Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J 2002, 21:3749-3759.
30. Nebigil C.G., Launay J.M., Hickel P., Tournois C., Maroteaux L. 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways. Proc Natl Acad Sci U S A 2000, 97:2591-2596.
31. Fonseca P.M., Shin N.Y., Brabek J., Ryzhova L., Wu J., Hanks S.K. Regulation and localization of CAS substrate domain tyrosine phosphorylation. Cell Signal 2004, 16:621-629.
32. Kim W., Seok Kang Y., Soo Kim J., Shin N.Y., Hanks S.K., Song W.K. The integrin-coupled signaling adaptor p130Cas suppresses Smad3 function in transforming growth factor-beta signaling. Mol Biol Cell 2008, 19:2135-2146.
33. Sandilands E., Frame M.C. Endosomal trafficking of Src tyrosine kinase. Trends Cell Biol 2008, 18:322-329.
34. Pedroja B.S., Kang L.E., Imas A.O., Carmeliet P., Bernstein A.M. Plasminogen activator inhibitor-1 regulates integrin alphavbeta3 expression and autocrine transforming growth factor beta signaling. J Biol Chem 2009, 284:20708-20717.
35. Jenkins G. The role of proteases in transforming growth factor-beta activation. Int J Biochem Cell Biol 2008, 40:1068-1078.
36. Mariggio S., Garcia-Hoz C., Sarnago S., De Blasi A., Mayor F., Ribas C. Tyrosine phosphorylation of G-protein-coupled-receptor kinase 2 (GRK2) by c-Src modulates its interaction with Galphaq. Cell Signal 2006, 18:2004-2012.
37. Magalhaes A.C., Dunn H., Ferguson S.S. Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br J Pharmacol 2012, 165:1717-1736.
38. Gong H., Shen B., Flevaris P., Chow C., Lam S.C., Voyno-Yasenetskaya T.A., et al. G protein subunit Galpha13 binds to integrin alphaIIbbeta3 and mediates integrin "outside-in" signaling. Science 2010, 327:340-343.
39. Brooke B.S., Habashi J.P., Judge D.P., Patel N., Loeys B., Dietz H.C. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008, 358:2787-2795.
40. Habashi J.P., Judge D.P., Holm T.M., Cohn R.D., Loeys B.L., Cooper T.K., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006, 312:117-121.
41. Olsen M.H., Wachtell K., Bella J.N., Liu J.E., Boman K., Gerdts E., et al. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am J Cardiol 2004, 94:1076-1080.
42. Cote N., Couture C., Pibarot P., Despres J.P., Mathieu P. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves. Eur J Clin Invest 2011, 41:1172-1179.
43. Nadir M.A., Wei L., Elder D.H., Libianto R., Lim T.K., Pauriah M., et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol 2011, 58:570-576.